Biotronik Brand Guidelines: Berlin’s 1963 Pacemaker Maker and “Excellence for Life”

A physicist, an engineer and the first German pacemaker.

Biotronik began in Berlin in 1963 with a pacemaker. English Wikipedia says the company grew out of the first German implantable pacemaker, the IP-03, developed at the Technische Universität Berlin by the physicist Max Schaldach, later a professor of biomedical technology at the University of Erlangen-Nuremberg, and the electrical engineer Otto Franke. The company says the two men officially founded Biotronik that year, and that the surgeon Emil Sebastian Bücherl carried out the first implant of their device in late 1963.

The company has stayed in the city. Biotronik says its headquarters later moved to the district of Neukölln, where they remain; German Wikipedia dates the move to 1976. Its legal form is Biotronik SE & Co. KG, and German Wikipedia describes it as a family company, a Familienunternehmen, without naming the owners. In 2012 Biotronik bought the old Postfuhramt, a historic brick postal building on Oranienburger Straße in Berlin-Mitte, according to both English and German Wikipedia, the German article citing the local paper Berliner Woche in 2014.

Growth abroad began within two decades. German Wikipedia says the company acquired a site at Lake Oswego, Oregon, in 1979 with the purchase of Stimulation Technology, Inc.; Biotronik’s own history says production facilities opened in Oregon, and offices across Europe, Asia and the Americas, between 1979 and 1982.

Pacemakers, defibrillators and remote monitoring.

Cardiac rhythm management has been the core from the start. In 1993 Biotronik brought out the first German implantable defibrillator, the Phylax 06, German Wikipedia says; the company describes it as the smallest ICD in the world at the time. In 1994 and 1995, English Wikipedia says, it added electrophysiology and vascular intervention products. The company says it opened a plant at Bülach, outside Zürich, in 1995 to make guide wires, stents and balloon catheters, and introduced Closed Loop Stimulation, a pacing method it describes as responding to physical and emotional activity, in the same year.

Remote care became the second theme. English Wikipedia says the Philos pacemaker family with telemetry received the CE mark in 2000, the year the first pacemaker with Home Monitoring was implanted. The company says that in 2003 it introduced Germany’s first pacemakers for cardiac resynchronization therapy, and German Wikipedia dates to 2005 an implantable defibrillator that sent electrogram data over the mobile phone network. In 2009, English Wikipedia says, the Home Monitoring system was nominated for the German Future Prize, the Deutscher Zukunftspreis; in 2007 the company received the EuroPCR Novelty Award from the European Association of Percutaneous Cardiovascular Interventions for its absorbable metal stents. German Wikipedia dates a hybrid drug-eluting stent to 2011, and English Wikipedia says the company released the Passeo-18 Lux drug-coated balloon for leg arteries in 2014.

Manufacturing now spans three regions. Biotronik says a manufacturing centre in Singapore began operations in 2016, alongside its sites in Europe and the United States, and that its products are developed and produced in Germany, the US and Singapore. In 2023 the US Food and Drug Administration approved its Prospera spinal cord stimulation system, and the company launched a business called Biotronik Neuro, according to both Wikipedia articles and the company. Current pacemaker and defibrillator ranges on its website carry names such as Amvia, Acticor and Rivacor, with BIOMONITOR insertable cardiac monitors.

Training has become part of the public face. English Wikipedia says the US arm opened an Education and Innovation Center in New York in February 2016, and German Wikipedia records a similar centre in Tokyo in 2018. In October 2025, English Wikipedia says, Biotronik and the University of Sydney began a three-year collaboration on digital and connected cardiac care.

How the category presents itself.

Cardiovascular device makers sell to a narrow audience: interventional cardiologists, electrophysiologists, cardiac surgeons, hospital buyers and regulators. Their visual language follows from that. A heart valve, a stent or a pacemaker is small, precise and usually hidden inside the body once it is in use, so the product photograph does much of the work. Valves, stents and leads tend to be shot in close-up on white or pale grey, lit to show struts, mesh and metal edges, with the device itself as the only subject.

The second register is the catheterisation laboratory. Brochures, websites and congress stands return again and again to the same scene: a patient table, a C-arm X-ray system arched over it, banks of monitors showing angiograms or mapping images, and clinicians in scrubs, lead aprons and caps. These pictures place the device in the room where it is used, without showing the patient’s body in detail.

Between the two sits illustration. Cutaway hearts, cross-sections of arteries and simplified diagrams of the conduction system explain where a valve sits, how a stent opens or how a lead reaches the heart. They are often rendered in reds and soft pinks against white, with the brand’s own colour kept for the device, the arrows and the type. Much of the copy is technical, built around product names, trial names and regulatory approvals as the companies state them.

Much of the category’s public life happens at medical congresses. TCT in the United States, EuroPCR in Paris and the ESC Congress of the European Society of Cardiology bring makers, clinicians and trade press together each year, and companies use them to show new devices and announce study results. The makers in this guide range from family-owned German engineering firms to Chinese groups with several listed subsidiaries, and their identities reflect that range more than any shared house style.

Excellence for Life, without the stents.

The company’s line is “Excellence for Life.” Biotronik says it adopted and trademarked the phrase in 2017 and made it part of its logo. The company writes its own name in capitals in running text.

In 2025 the business narrowed. In February Biotronik agreed to sell its Vascular Intervention business to Teleflex, English Wikipedia says, and the company states that the business, including Biotronik AG in Bülach, passed to Teleflex effective 1 July 2025. The Chester County news site MyChesCo reported on 2 July 2025 that Teleflex had completed the purchase of substantially all of the business earlier than expected. Coronary and peripheral lines such as the Orsiro Mission drug-eluting stent, the Pantera Lux drug-coated balloon and the PK Papyrus covered stent are now Teleflex products. Biotronik’s website now lists cardiac rhythm management, electrophysiology, neuromodulation and Micro Systems Technologies, a unit it says supplies components such as ceramic substrates, batteries and feedthroughs to the active implant industry.

There have been legal cases in the United States. On 22 July 2022 the US Department of Health and Human Services Office of Inspector General reported that the Oregon-based subsidiary Biotronik Inc. had agreed to pay to settle allegations under the False Claims Act that it paid kickbacks to physicians to induce the use of its implantable cardiac devices.

For a design guide, Biotronik shows how a family engineering firm can keep one founding product, the pacemaker, at the centre of its identity for more than sixty years. Compare Medtronic, the Minneapolis pacemaker maker, and MicroPort, which bought the former Sorin pacemaker business. For this guide we use a deep navy, a lead grey and a coral with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Biotronik’s identity on hand — save it to a board in the Made Good inspiration library.